H epatocellular carcinoma (HCC) is the fastest increasing cause of cancer-related deaths in the United States. 1, 2 In addition to the rising incidence rates, and despite advances in diagnosis and treatment, the overall prognosis of HCC remains poor with an estimated 5-year survival rate of only 12%. 1 A meta-analysis of observational studies reported that HCC treatment is underused, with only 22% and 53% of patients receiving curative and noncurative treatments, respectively. 3 However, there are few data on the natural history and determinants of survival in patients with untreated HCC, particularly those with hepatitis C virus (HCV) infection. These data are useful to test and potentially modify existing tumor prognosis classifications, identify subgroups that are likely to benefit in future clinical trials, and quantify the extent of lead time related to HCC surveillance.
Several non-U.S. studies reported heterogeneous survival rates among patients with untreated HCC, most commonly using the Barcelona Clinic Liver Cancer (BCLC) staging as a prognostic guide. [4] [5] [6] [7] However, additional variables not included in the BCLC staging, such as a-fetoprotein (AFP) level, have been implicated to predict survival in untreated HCC cohorts. 5, 8 In the United States, where HCV infection is the major cause of HCC, 1 screening for HCC remains a topic of much debate. 9, 10 This is because most of the evidence supporting routine surveillance stems from observational cohort and case control studies with no randomized trials on surveillance in patients with HCV. 9, 11, 12 The possibility of lead time bias is a main limitation of these studies and the quantification and adjustment for this bias in the presence of HCC treatment is difficult. Studying patients with untreated HCC who were detected with and without surveillance allows for a better understanding of the extent of lead time bias.
Using data from a national cohort of 518 veteran patients with untreated HCC, we investigated the natural history of HCC in a mostly HCV-positive cohort, identified prognostic variables associated with survival outside the BCLC classification, and studied the impact of HCC surveillance on survival in the absence of treatment.
Materials and Methods

Data Sources
Study data were obtained from manual review of electronic medical records (EMR) combined with automated Department of Veterans Affairs (VA) administrative data files. EMR reviews were conducted in the VA 13 Based on a desired sample size of 1500 cases with definite HCC, we selected a random computer-generated sample of patients with suspected HCC for structured chart review to determine and verify the study eligibility criteria, and included only patients with HCC diagnosis by histopathology or imaging criteria according to the 2005 American Association for the Study of Liver Disease or European Association for the Study of Liver Disease guidelines. 14, 15 We also required the following additional inclusion criteria: recent VA healthcare utilization (at least 1 inpatient or outpatient encounter at any VA facility within the 1 year before the date of HCC diagnosis), and no HCC diagnosis made before the study period. We reviewed charts of 2719 patients with suspected HCC to arrive at 1500 unique study subjects with verified HCC who met the study criteria (Figure 1 ).
Patient Characteristics
We ascertained demographic features (age, gender, and race), clinical characteristics (etiology and severity of liver disease, BCLC stage at diagnosis), and medical and mental conditions from EMR review. We defined confirmed cirrhosis based on the following hierarchy in descending order: liver biopsy results at any time before or at the time of diagnosis of HCC, features suggestive of cirrhosis on abdominal imaging, clinical complications of cirrhosis (ascites, hepatic encephalopathy, varices), laboratory evidence consisting of abnormal values of 2 of 3 laboratory tests (albumin <3.0 g/L, platelets <200,000/L, international normalized ratio >1.1 between 6 months before and 4 weeks after HCC diagnosis), or an aspartate aminotransferase to platelet ratio index score >2.0. 
Risk Factors for Hepatocellular Carcinoma
We defined HCV infection as positive anti-HCV antibody or HCV RNA, and hepatitis B virus (HBV) infection as at least 1 instance of positive HBV surface antigen. Alcohol abuse was defined as history of more than 3 drinks daily, documented alcoholism or alcohol abuse by a health care provider, participation in a substance abuse treatment program, or a history of alcoholic hepatitis. Nonalcoholic fatty liver disease was defined by histopathology (steatosis on biopsy) or presence of metabolic syndrome in the absence of other causes of chronic liver disease (HCV, HBV, alcohol abuse, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hemochromatosis, or Wilson disease). We defined metabolic syndrome using U.S. National Cholesterol Education Program Adult Treatment Panel III guidelines, 17 except for replacing the elevated waist circumference criterion with body mass index >28.8 kg/m 2 in both men and women. 18 
Hepatocellular Carcinoma Surveillance
Patients were classified as having received HCC surveillance if they underwent abdominal imaging and/or AFP surveillance within 2 years of HCC diagnosis. Surveillance by imaging was defined as receipt of any liver ultrasound, computed tomography scan, or magnetic resonance imaging in the 2 years before HCC diagnosis with surveillance as the listed indication, in the setting of liver transplantation evaluation, follow-up of a known nonmalignant liver mass, or imaging in a patient with indication listed only as "cirrhosis." AFP surveillance was defined as receipt of 2 or more AFP tests at least 6 months apart in the 2 years before HCC diagnosis.
Those who were diagnosed with HCC as a result of symptoms, imaging for an indication other than those listed previously, or incidentally during an evaluation for other signs and symptoms were classified in the nonsurveillance group. Two hepatologists (HE-S, SM) manually reviewed the EMR including all imaging reports to determine the presence of prediagnosis HCC surveillance.
Statistical Analysis
Survival time was defined as time in months from HCC diagnosis to death, last VA encounter, or end of study period (October 31, 2014). To identify predictors of overall survival (OS), we compared the demographic, clinical, and tumor features between groups of patients with untreated HCC who survived <12 and !12 months using chi-square or Fisher exact test for categorical variables.
Stepwise Cox regression was performed to identify variables that were associated with 12-month and OS. Potential predictors (age, race, BCLC stage, cirrhosis status, disease etiology variables, MELD score, AFP level, and surveillance status) that were significantly associated with survival in univariate analyses (P < .1) were used as input variables. Race, age, surveillance, and variables with P < .05 in multivariable analyses were retained in the final models. Hazard ratios (HR) and their 95% confidence intervals (CI) were calculated.
To further examine the possible effect of HCC surveillance on observed survival among patients with untreated HCC, Kaplan-Meier analysis was used to compare OS by BCLC stage in patients with and without HCC surveillance. Mean and median survival times were calculated and log-rank tests were performed to compare the distribution among patient groups. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
Of 1500 patients with verified HCC, 518 patients did not receive curative or palliative HCC treatment including resection, liver transplantation, ablation, chemoembolization, or antineoplastic agents (Figure 1 ) and the other 982 received at least 1 treatment specific for HCC. As compared with patients with HCC who received treatment, the no treatment group was older, had more advanced BCLC stage at time of diagnosis, higher Child Pugh score, and less HCV ( Table 1) .
The study cohort consisted of 518 patients without any HCC-specific treatment. A total of 14 (2.7%) patients had BCLC stage 0/A, 76 (14.7%) had stage B, 227 (43.8%) had stage C, and 166 (32.0%) had stage D disease at the time of diagnosis ( Table 2 ). The main reasons for absence of HCC treatment in patients with early stage disease (0/A/B) were treatment refusal (37.8%), medical ineligibility based on comorbidities (23.3%), disease progression before planned treatment (10.0%), or loss to follow-up (10.0%). The mean age at time of HCC diagnosis was 65.7 years, and all but 2 participants were male (99.6%). Most patients were non-Hispanic whites (59.5%), followed by African Americans (28.0%) and Hispanics (9.6%). Most patients had HCV (314; 60.6%) or alcohol abuse (411; 79.3%), whereas nonalcoholic fatty liver disease (48; 9.3%), HBV (27; 5.2%), and other causes (18; 3.5%) of liver disease were less common. Most patients had cirrhosis (426; 82.2%) and were Child-Pugh Class B (227; 43.8%) at time of HCC diagnosis.
In multivariate analyses, BCLC stage was highly predictive of 12-month mortality risk (stage A vs D: adjusted HR, 0.16; 95% CI, 0.07-0.40). Similarly, MELD score 10-19 versus <10 (adjusted HR, 1.60; 95% CI, 1.27-2.02), MELD score !20 versus <10 (adjusted HR, 1.83; 95% CI, 1.25-2.68), and AFP level !1000 versus <10 (adjusted HR, 1.89; 95% CI, 1.44-2.49) were significantly associated with 12-month mortality. There was a nonsignificant trend toward decreased mortality risk in patients who were enrolled in HCC surveillance programs (adjusted HR, 0.84; 95% CI, 0.66-1.06).
Similar results were found with overall mortality risk ( Table 3) .
Most patients (99.4%) died within the observation period, with a median OS of 3.6 months (interquartile range, 1.4-9.1) and mean OS of 7.6 months (standard error, 0.49) and a range of 0.1-84.5 months (Table 4 , Figure 2 ). Only 95 (18.3%) participants were alive at 12 months following HCC diagnosis. The 12-month survival rates for BCLC stage 0/A, B, C, and D disease were 64%, 37%, 13%, and 7%, respectively (Supplementary Table 1 ). Age, race, presence of cirrhosis, etiology of liver disease, performance status, degree of hepatic encephalopathy, or enrollment in surveillance programs were not associated with survival at 12 months in univariate analyses. In contrast, stage D disease, Child-Pugh Class C, and elevated MELD and AFP levels were associated with decreased rates of 12-month survival (P < .0001) ( Table 2) .
Of all patients, 144 (27.8%) underwent HCC surveillance, and these patients were more likely to be diagnosed with earlier stage BCLC 0/A/B disease (38/144; 26.4%) compared with those who did not receive surveillance (50/348; 14.4%; P ¼ .0006) (Supplementary Table 2 ). The difference in median OS between those who were enrolled in surveillance programs and those who were not was only 1.8 months. Within patients in whom BCLC stage was known, this survival difference ranged from 0.2 months for stage 0/A/B to 0.5 months in stage C, to 0.8 months in stage D (Table 5) .
The Kaplan-Meier curves showed the probability of survival stratified by BCLC stage (Figure 2 ) and surveillance status ( Figure 3 ). As expected, those with lower BCLC stage at diagnosis had significantly longer median OS compared with those with higher stage disease (BCLC 0/A, 13.4 months; BCLC B, 9.5 months; BCLC C, 3.4 months; BCLC D, 1.6 months; log-rank P < .0001). Furthermore, pairwise comparison showed significant differences in survival between patients with contiguous BCLC stages (B vs C, P < .0001; C vs D, P ¼ .0001) (Table 4, Figure 2 ). Patients with pre-HCC surveillance also had significantly longer median OS compared with those not in surveillance programs (5.2 vs 3.4 months; log-rank P ¼ .021); however, all except 3 patients died within the observation period ( Figure 3 , Table 5 ). Of note, there was no difference in median OS in earlier stage disease (0/A/B) when stratified by the presence or absence of surveillance (10.3 vs 10.5 months, respectively; log-rank P ¼ .917). Similarly, stratification by surveillance status in higher stage disease showed no difference in mortality (log-rank P ¼ .375) ( Table 5 ).
Discussion
Studying the natural history of untreated HCC is critical for understanding the prognosis and prognostic factors of HCC and the contribution of surveillance to lead time bias. 19 With the exception of few prior studies, 5,7 only 1 of which focused on HCV-related HCC, our understanding of the natural history of HCC is largely limited to the reported OS among patients observed in the placebo or nontreatment arms of clinical trials. 4 In this study, OS in 518 patients with untreated HCC was, although heterogeneous, very short even among those with early stage disease or those in surveillance programs. Specifically, patients with earlier stage HCC who were diagnosed on the basis of surveillance gained no additional survival benefit in the absence of HCC treatment.
Our study confirmed the importance of BCLC classification as an important predictor of OS. The BCLC classification combines tumor features, liver function, and functional status to estimate HCC prognosis and guide treatment decisions. 20 In our study, BCLC stage was significantly associated with OS with significant differences among patients in contiguous stages (B vs C and C vs D), supporting the utility of this classification system. Additionally, we also found that others factors, such as MELD scores and AFP levels, confer additional independent prognostic value in untreated patients with HCC. These findings are supported by previous studies describing an association between HCC survival and MELD score components including total bilirubin, 8, 21 elevated blood urea nitrogen levels, 8 and elevated international normalized ratio 5 and AFP levels. 5, 8 Because BCLC stage correlates with tumor burden, AFP with tumor biology, and MELD with degree of cirrhosis, each of these components represents a unique aspect of the individual patient with HCC. In our study, these variables were the most significant predictors of survival in untreated HCC, and it is possible that combining 1 or more in future prospective studies might result in even greater prognostic ability.
Most patients in this study (75.8%) had advanced BCLC stage C or D disease at time of cancer diagnosis, with a median OS of 3.4 and 1.6 months, respectively. However, even for patients with BCLC stages 0/A and B, the median survival was only 13.4 and 9.5 months, respectively. Although it may seem surprising that neither curative nor palliative therapy was used in patients with early stage disease, a previous systematic review of patients with HCC found that only 22% and 53% received curative or palliative therapy, respectively, and only 59% of the subgroup with early HCC received curative treatment. 3 We identified and reported documented and inferred reasons for not receiving HCC treatment. Our reported survival rates were generally shorter compared with those of other studies. In the study by Cabibbo et al 5 of 320 predominately HCVrelated Italian patients with HCC and the study by Gainnini et al 7 of 600 predominately HBV-related Italian patients with HCC, median OS was 6.8 and 9 months, respectively. The reasons for the observed shorter survival compared with other studies likely include the unselected nature of our study population, which represents the spectrum of HCC irrespective of extent of prior care and the high burden of comorbid conditions (eg, alcohol abuse in 79% of patients).
Approximately 28% of the study cohort received prediagnosis surveillance. These patients were more likely to have earlier stage disease (BCLC 0/A/B), be alive at 12 months, and have longer OS compared with those who did not receive surveillance. Lead time likely explains these findings given that no HCC treatment was received, but it does not seem to add more than 1 to 2 months to the observed OS compared with stage-matched cases who did not receive HCC surveillance. Thus, surveillance did not merely identify patient with HCC with less aggressive tumors who were destined to do well as part of their natural history. We believe our data provide support to a real survival benefit associated with HCC surveillance programs, programs that result in diagnosis at an earlier stage followed by stage-appropriate therapy as reported by previous studies. [22] [23] [24] [25] [26] In our study, the overall 1-, 2-, and 3-year survival rates were 64%, 36%, and 7%, respectively, for BCLC stage A disease. Little is known about the course of untreated small HCC (a single lesion <5 cm in diameter), an increasingly important group given the spread of surveillance programs. 26 Curative treatment of early or small HCC is associated with a 50%-70% 5-year survival rate 1, 16, [27] [28] [29] [30] ; however, in the absence of randomized prospective control subjects, it is possible that patients with early or small HCC have a favorable survival irrespective of treatment. 31, 32 Within the confines of an overall poor survival with HCC, predicting outcomes in small HCC seems unreliable, and it is possible that some patients with small HCC have relatively long survival irrespective of treatment. Further studies are needed to elucidate prognostic features in this growing subclass of small HCC.
This study has a few limitations. The retrospective data collection could have led to misclassification of HCC stage and some of the prognostic variables. However, the availability of detailed EMRs including laboratory results, radiology images and reports, and pathology reports from all VA facilities coupled with the systematic, standardized, and thorough data abstraction has minimized the subjectivity of defining the study variables. Our largely male cohort did not allow for differences in gender to be studied and resulted in limited generalizability to women. 7 We used a wide definition of surveillance to account for change in HCC surveillance guidelines during the study period and therefore an undetermined degree of misclassification could have occurred. 33, 34 Finally, most patients had advanced disease at time of diagnosis and did not have HCC surveillance, which limited the power of our analyses for the subset with early stage disease and prior HCC surveillance. Although many VA patients get their care exclusively at the VA, some patients with dual insurance coverage (eg, Medicare for elderly patients) may get some of their care outside the VA. However, we identified treatment received outside the VA in our review of the medical records. This is the only U.S. study regarding the natural history of patients with untreated HCC, and the largest on this topic in an HCV-infected cohort. MELD scores and AFP levels predicted mortality independent of BCLC staging. Those who received prediagnosis HCC surveillance had earlier stage disease compared with those not in surveillance programs. However, the survival benefit without HCC treatment was quiet modest (1.8 months overall) and therefore unlikely to explain the effectiveness of surveillance reported by most previous observational studies. These findings argue surveillance programs in combination with more precise risk stratification are needed for appropriate patient management and improved HCC outcomes. 
